Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ANK-700
Therapeutic Area: Neurology Product Name: ANK-700
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for ANK-700, an antigen-specific drug candidate for the treatment of multiple sclerosis (MS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KAN-101
Therapeutic Area: Immunology Product Name: KAN-101
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 22, 2020
Details:
The collaboration aims developing therapeutics for autoimmune diseases, to include Anokion’s lead antigen-specific drug candidate, KAN-101, for the treatment of celiac disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KAN-101
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
Details:
First-in-human study designed to evaluate the safety and tolerability of KAN-101 in patients with celiac disease on a gluten-free diet (GFD).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KAN-101
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2020
Details:
Anokion plans to initiate its multi-center Phase 1 study for KAN-101 in people with celiac disease in the first quarter of 2020.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
